Motilent
@motilent.bsky.social
220 followers 83 following 130 posts
Delivering innovative services for quantitive investigation of the gut. Email: [email protected]
Posts Media Videos Starter Packs
motilent.bsky.social
We’re at #BSGlive25! If you’d like to book a chat with the team drop us an email: [email protected]

Don't miss: Evaluating pTRACK: A Novel Tool for Assessing Perianal Crohn’s Disease through MRI Metrics
📍 TODAY Exhibition Hall 4
⏰ 12:45 - 13:45
motilent.bsky.social
We’re at #BSGLive25! If you’d like to book a demo or chat with the team onsite drop us an email at [email protected]
motilent.bsky.social
Using GIQuant and cine-MRI may support earlier identification of strictures unlikely to respond to medical therapy potentially streamlining decision-making around surgery, dilation, or emerging anti-fibrotic trials.

Excellent work K.J. Beek et al!
motilent.bsky.social
This suggests that quantified pre-stricture motility measured via cine-MRI could serve as a non-invasive imaging biomarker to help distinguish stricture subtypes. This could be valuable in fibrostenotic Crohn’s, where differentiating between fibrosis & inflammation is often invasive & ambiguous.
motilent.bsky.social
Key findings:
Motility in pre-stricture dilatations was significantly higher in chronic vs. inflammatory strictures (289.5AU vs. 113.1AU, p=0.004). Notably, no significant difference was seen within the strictures themselves.
pes.
motilent.bsky.social
👉 Cine or motility MRI was performed prior to stricture surgery
👉 Motility of 30 strictures and 15 pre-stricture dilatations was quantified using GIQuant
👉 Resection specimens were scored histologically as predominantly inflammatory, mixed, or chronic (non-inflammatory)
motilent.bsky.social
Advances in fibrostenotic Crohn’s Disease - what information is hidden up-stream of the stricture out of reach of the endoscope ?

A recent prospective study involving 28 Crohn’s Disease (CD) patients explored the potential of cine-MRI to non-invasively characterise stricture subtypes:

👇
motilent.bsky.social
Don’t miss poster EP522 Virtual 3D Reconstruction Technology to Improve the Surgical Management of Perianal Crohn’s Disease – A Trial Protocol and Initial Results.

Catch the presentation TODAY at monitor 8, Sails Pavilion, Upper Level at 2:52 PM – 2:57 PM

#ASCRS2025 @ascrs.bsky.social
motilent.bsky.social
Good morning #ASCRS2025 attendees! We're at booth 514 - stop by for a demo of vEUA (Virtual EUA) our 3D modelling technology for perianal fistulas & low rectal cancer.

vEUA enhances communication between #surgeons , #patients & #radiologists leading to better patient outcomes.

#ASCRS25
motilent.bsky.social
PRODUCT ANNOUNCEMENT: Introducing Motilent Bridge!

Ultrasound data is notoriously difficult to move, store & share in clinical trials, training & clinic

Solution 👉 Motilent Bridge a fast,simple way to securely store & transfer imaging.

#ddw2025 #ddw25 #clinicaltrials #ultrasound
motilent.bsky.social
Good Morning #ddw2025 attendees! Be sure to swing by Jonathan Dillman's poster #1937 TODAY 12:30 👉 1:30 pm to hear about bringing Doppler into the 21st century!

@cincykidsrad.bsky.social
motilent.bsky.social
Are both of the arrows pointing to #crohnsdisease? You have 5 seconds..

🤔 The MRI below shows thickening of the bowel wall at the terminal ileum
💭 There is also a thickened bowel loop on the top left
...both #crohns?

⏱️ 5..4..3..2..1..

#ddw25 attendees did you guess correctly?

#ddw2025 #IBD
motilent.bsky.social
Issue 15 of The Motilent Monthly Digest is out! 📧

Click to read more: open.substack.com/pub/motilent...

#newsletter #IBD #medtech
motilent.bsky.social
T-18 days to Digestive Disease Week® (DDW)!

Looking forward to seeing lots of you there - remember to stop by booth 1719 to meet the team and find out what's new at Motilent or book a demo slot here 👉 calendly.com/info-91i/ddw...

#ddw #ddw2025 #ddw25 #ibd
motilent.bsky.social
Practically, overlooking the range of motion that a stricture and dilation is capable of with a limited number of anatomical snap-shots can lead us to underestimating or even missing the disease.

All strictures are created different and remember...
👉Strictures aren't always structural
motilent.bsky.social
Bowel peristalsis becomes abnormal both at the stricture and in the upstream at the dilation which can reflect chronicity, reversibility and even explanation of symptoms.
motilent.bsky.social
Imaging in fibrostenotic Crohn's Disease - What you need to think about (post 3/3)

What many people don't realise is that FSCD has a large functional component that makes sense conceptually but is not often talked about (beyond pain!).
motilent.bsky.social
💪 All on Entrolytics

Come see us at Digestive Disease Week® (DDW) or get in touch to learn more 👉 we are here to help with your trials, clinic or research.
motilent.bsky.social
Imaging in fibrostenotic Crohn's Disease - what you need to do (post 2/3)

Motilent have been working with precision imaging for a long time now. Here's how we tackle fibrostenotic Crohn's disease.

1. Use the right tools
2. Capture with an integrated report
3. Keep all your data in 1 place
motilent.bsky.social
- But we can't get imaging... Oncology, cardiology, and neurology have solved this problem. The scanners are out there. We need to work together to create compelling data to get access.
motilent.bsky.social
- Can't you just measure fibrosis? No! While advanced methods are on the way we need to focus on what we can measure (length, volume, peristalsis) and use validated scores like MaRIA where possible to assess the inflammatory component.
motilent.bsky.social
🤔 FAQ's
- What about IUS? Great is skilled hands but the lack of bowel prep (to distend the lesion) and difficulty in measuring lesion length may harm repeatability. In practice, MRI and IUS work wonderfully together.
motilent.bsky.social
At the moment you need to measure:
1) Length of the lesion ICC 0.85
2) Bowel wall thickness ICC 0.58
3) Size of pre-stricture dilation ICC 0.74

Collectively these provide objective scores to assess stricture morphology during treatment. The best part is this is routinely done in clinical practice!
motilent.bsky.social
You need cross-sectional imaging - specifically MRI

Objective, cross-sectional and safe non-invasive imaging is the key to 1) identifying, 2) staging and 3) monitoring treatment response in fibrostenotic Crohn's.

#clinicaltrials